Drug Profile
Nemolizumab - Chugai Pharmaceutical
Alternative Names: Anti-IL-31-receptor-monoclonal-antibody - Chugai Pharmaceutical; CD-14152; CIM 331; IL-31RA monoclonal antibody - Chugai Pharmaceutical; M 5250; M 5250B; MitchgaLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Galderma; Maruho
- Class Anti-inflammatories; Antipruritics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 31 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Preregistration Prurigo nodularis; Pruritus
- Phase II Scleroderma
Most Recent Events
- 14 Feb 2024 Preregistration for Atopic dermatitis (In adolescents, In the elderly, In adults) in European Union (SC) prior to February 2024
- 14 Feb 2024 Preregistration for Atopic dermatitis (In adolescents, In the elderly, In adults) in USA (SC) prior to February 2024
- 14 Feb 2024 Preregistration for Prurigo nodularis in European Union (SC) prior to February 2024